| scholarly article | Q13442814 |
| P50 | author | Nabeel Bardeesy | Q30004507 |
| Dawang Zhou | Q37382920 | ||
| P2093 | author name string | Joseph Avruch | |
| Nabeel Bardeesy | |||
| P2860 | cites work | A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP) | Q24293710 |
| Yap1 acts downstream of α-catenin to control epidermal proliferation | Q24294904 | ||
| The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells | Q24296824 | ||
| Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control | Q24299106 | ||
| Kibra functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded | Q24299457 | ||
| Ajuba LIM proteins are negative regulators of the Hippo signaling pathway | Q24304074 | ||
| TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway | Q24307937 | ||
| Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage | Q24314457 | ||
| Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein | Q24323326 | ||
| The WW domain of Yes-associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules | Q24323939 | ||
| TEAD mediates YAP-dependent gene induction and growth control | Q24336045 | ||
| A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator | Q24534123 | ||
| α-catenin is a tumor suppressor that controls cell accumulation by regulating the localization and activity of the transcriptional coactivator Yap1 | Q24613385 | ||
| Hippo pathway-independent restriction of TAZ and YAP by angiomotin | Q24614424 | ||
| TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm | Q24632716 | ||
| Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach | Q24633776 | ||
| Expression of Yes-associated protein in common solid tumors | Q24657592 | ||
| Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon | Q24682018 | ||
| WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus | Q28179264 | ||
| Opposing roles of angiomotin-like-1 and zona occludens-2 on pro-apoptotic function of YAP | Q28241192 | ||
| Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product | Q28245300 | ||
| The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP | Q28266862 | ||
| SCALLOPED interacts with YORKIE, the nuclear effector of the hippo tumor-suppressor pathway in Drosophila | Q28271058 | ||
| Stem cells, self-renewal, and differentiation in the intestinal epithelium | Q28294807 | ||
| The WW domain: a signalling site in dystrophin? | Q28306741 | ||
| Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size | Q28507019 | ||
| The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation | Q28507317 | ||
| YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation | Q28507494 | ||
| Notch and Wnt signals cooperatively control cell proliferation and tumorigenesis in the intestine | Q28586202 | ||
| Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver | Q28587974 | ||
| Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression | Q28591557 | ||
| YAP1 increases organ size and expands undifferentiated progenitor cells | Q28592519 | ||
| E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. | Q28972461 | ||
| Elucidation of a universal size-control mechanism in Drosophila and mammals | Q29618935 | ||
| hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts | Q29620457 | ||
| Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma | Q33611696 | ||
| YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway | Q33644875 | ||
| Kibra is a regulator of the Salvador/Warts/Hippo signaling network | Q33754234 | ||
| Zyxin links fat signaling to the hippo pathway | Q33930545 | ||
| The WW domain protein Kibra acts upstream of Hippo in Drosophila. | Q34099040 | ||
| Willin/FRMD6 expression activates the Hippo signaling pathway kinases in mammals and antagonizes oncogenic YAP. | Q34191953 | ||
| Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor | Q34207272 | ||
| The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program | Q34244244 | ||
| The Lats2 tumor suppressor augments p53-mediated apoptosis by promoting the nuclear proapoptotic function of ASPP1 | Q34244270 | ||
| The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. | Q34418866 | ||
| Hippo signaling: growth control and beyond | Q34625638 | ||
| Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance | Q35621419 | ||
| The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma | Q35642059 | ||
| In vivo regulation of Yorkie phosphorylation and localization. | Q36663448 | ||
| Hippo signaling in organ size control | Q36793377 | ||
| Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription | Q37259684 | ||
| Rassf family of tumor suppressor polypeptides. | Q37353443 | ||
| The RASSF proteins in cancer; from epigenetic silencing to functional characterization | Q37432498 | ||
| Upstream regulation of the hippo size control pathway | Q37771533 | ||
| Mst1/2 signalling to Yap: gatekeeper for liver size and tumour development | Q37811893 | ||
| Tissue-resident adult stem cell populations of rapidly self-renewing organs | Q37812949 | ||
| Molecular identification and targeting of colorectal cancer stem cells | Q37839545 | ||
| Facultative stem cells in liver and pancreas: fact and fancy. | Q37839897 | ||
| Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation | Q37880216 | ||
| Deciphering tumor-suppressor signaling in flies: genetic link between Scribble/Dlg/Lgl and the Hippo pathways | Q37950608 | ||
| Hippo signaling: a hub of growth control, tumor suppression and pluripotency maintenance | Q37950609 | ||
| Hippo signaling in Drosophila: recent advances and insights | Q37968995 | ||
| PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. | Q38357857 | ||
| Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. | Q39514897 | ||
| The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. | Q39592989 | ||
| YAP is a candidate oncogene for esophageal squamous cell carcinoma | Q39626574 | ||
| Cytoplasmic ASPP1 inhibits apoptosis through the control of YAP. | Q39637300 | ||
| The FERM-domain protein Expanded regulates Hippo pathway activity via direct interactions with the transcriptional activator Yorkie | Q39872336 | ||
| YAP regulates neural progenitor cell number via the TEA domain transcription factor | Q39915491 | ||
| Yes-associated protein (YAP) functions as a tumor suppressor in breast. | Q39962753 | ||
| The TEAD/TEF family of transcription factor Scalloped mediates Hippo signaling in organ size control | Q40015415 | ||
| The RUNX2 transcription factor cooperates with the YES-associated protein, YAP65, to promote cell transformation | Q40144929 | ||
| The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling | Q41888008 | ||
| Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene | Q42064207 | ||
| Connective tissue growth factor autocriny in human hepatocellular carcinoma: oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation | Q42492308 | ||
| Phosphorylation-independent repression of Yorkie in Fat-Hippo signaling. | Q42625092 | ||
| The TEAD/TEF family protein Scalloped mediates transcriptional output of the Hippo growth-regulatory pathway | Q47071830 | ||
| Liver regeneration | Q63664803 | ||
| Differences in Yes-associated protein and mRNA levels in regenerating liver and hepatocellular carcinoma | Q82102323 | ||
| Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer | Q83169055 | ||
| P433 | issue | 6 | |
| P921 | main subject | colon cancer | Q18555025 |
| overexpression | Q61643320 | ||
| P1104 | number of pages | 7 | |
| P304 | page(s) | 1090-1096 | |
| P577 | publication date | 2012-03-15 | |
| P1433 | published in | Cell Cycle | Q1254166 |
| P1476 | title | YAP oncogene overexpression supercharges colon cancer proliferation | |
| P478 | volume | 11 |
| Q36798037 | A genetic variant in large tumor suppressor kinase 2 of Hippo signaling pathway contributes to prognosis of hepatocellular carcinoma |
| Q24337135 | A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer |
| Q54247052 | Alterations in the NF2/LATS1/LATS2/YAP Pathway in Schwannomas. |
| Q38941672 | Angiomotin decreases lung cancer progression by sequestering oncogenic YAP/TAZ and decreasing Cyr61 expression |
| Q92696961 | Calotropin activates YAP through downregulation of LATS1 in colorectal cancer cells |
| Q86544507 | Clinical and prognostic significance of Yes-associated protein in colorectal cancer |
| Q51611915 | Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma. |
| Q36304149 | Convergent signaling in the regulation of connective tissue growth factor in malignant mesothelioma: TGFβ signaling and defects in the Hippo signaling cascade |
| Q34252516 | Curcumin: a potential candidate in prevention of cancer via modulation of molecular pathways |
| Q49171030 | Downregulation of YAP inhibits proliferation and induces apoptosis in Eca-109 cells |
| Q43651454 | Dual roles of yes-associated protein (YAP) in colorectal cancer |
| Q26774473 | Emerging role of Hippo pathway in gastric and other gastrointestinal cancers |
| Q36901489 | Emerging roles of TEAD transcription factors and its coactivators in cancers |
| Q50747723 | Expression patterns of Oct4, Cdx2, Tead4, and Yap1 proteins during blastocyst formation in embryos of the marsupial, Monodelphis domestica Wagner. |
| Q37629024 | G-protein-coupled receptors mediate ω-3 PUFAs-inhibited colorectal cancer by activating the Hippo pathway |
| Q28088294 | Hippo/YAP pathway for targeted therapy |
| Q28487649 | Histone acetylation-mediated regulation of the Hippo pathway |
| Q90720640 | Human Colorectal Cancer from the Perspective of Mouse Models |
| Q38605108 | Hypoxia-inducible factor 2α (HIF-2α) promotes colon cancer growth by potentiating Yes-associated protein 1 (YAP1) activity |
| Q61809721 | Loss of Yes-associated Protein Represents an Aggressive Subtype of Colorectal Cancer |
| Q55516291 | Lysyl oxidase: A colorectal cancer biomarker of lung and hepatic metastasis. |
| Q33720204 | Mammalian STE20-like kinase 2, not kinase 1, mediates photoreceptor cell death during retinal detachment |
| Q50707850 | Molecular Alterations and Expression Dynamics of LATS1 and LATS2 Genes in Non-Small-Cell Lung Carcinoma. |
| Q35591698 | NDR functions as a physiological YAP1 kinase in the intestinal epithelium |
| Q34770004 | Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells |
| Q40545042 | RUNX3 is a novel negative regulator of oncogenic TEAD-YAP complex in gastric cancer |
| Q36508081 | Restriction of intestinal stem cell expansion and the regenerative response by YAP. |
| Q61805753 | Role of inhibitor of yes-associated protein 1 in triple-negative breast cancer with taxol-based chemoresistance |
| Q92493288 | STUB1 suppresseses tumorigenesis and chemoresistance through antagonizing YAP1 signaling |
| Q35885488 | Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients |
| Q47445431 | Significant expression of tafazzin (TAZ) protein in colon cancer cells and its downregulation by radiation. |
| Q34571020 | TAZ expression as a prognostic indicator in colorectal cancer |
| Q28078129 | Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy |
| Q36286883 | The Hippo component YAP localizes in the nucleus of human papilloma virus positive oropharyngeal squamous cell carcinoma. |
| Q36278724 | The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression |
| Q37190816 | The clinical significance of forkhead box protein A1 and its role in colorectal cancer |
| Q92714964 | The expressions of YAP1, β-catenin and survivin in colon cancer tissues and their clinical significance |
| Q58768991 | The role of YAP/TAZ activity in cancer metabolic reprogramming |
| Q49923462 | The role of free-fatty acid receptor-4 (FFA4) in human cancers and cancer cell lines |
| Q27305276 | The tumor suppressor gene, RASSF1A, is essential for protection against inflammation -induced injury |
| Q36757322 | Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1 |
| Q90567225 | Two Opposing Faces of Retinoic Acid: Induction of Stemness or Induction of Differentiation Depending on Cell-Type |
| Q37034046 | Underexpression of LATS1 TSG in colorectal cancer is associated with promoter hypermethylation |
| Q38814667 | Unraveling the expression of the oncogene YAP1, a Wnt/beta-catenin target, in adrenocortical tumors and its association with poor outcome in pediatric patients. |
| Q42376399 | Upregulation of Yes-associated protein and transcriptional co-activator with PDZ-binding motif influences the behavior of LOVO human colon adenocarcinoma cells |
| Q41094610 | VGLL4 Selectively Represses YAP-Dependent Gene Induction and Tumorigenic Phenotypes in Breast Cancer |
| Q42357352 | WWC3: the bridge linking Hippo and Wnt pathways in lung cancer |
| Q36726132 | YAP induces cisplatin resistance through activation of autophagy in human ovarian carcinoma cells |
| Q64233974 | YAP1 overexpression is associated with poor prognosis of breast cancer patients and induces breast cancer cell growth by inhibiting PTEN |
| Q37269206 | Yes-associated protein (YAP) increases chemosensitivity of hepatocellular carcinoma cells by modulation of p53. |
| Q38733712 | Yes-associated protein/TEA domain family member and hepatocyte nuclear factor 4-alpha (HNF4α) repress reciprocally to regulate hepatocarcinogenesis in rats and mice |
| Q34028517 | α-catenin. A tumor suppressor beyond adherens junctions |
Search more.